HRP20171678T1 - Postupci za smanjenje prejedanja ili kompulzivnog jedenja - Google Patents
Postupci za smanjenje prejedanja ili kompulzivnog jedenja Download PDFInfo
- Publication number
- HRP20171678T1 HRP20171678T1 HRP20171678TT HRP20171678T HRP20171678T1 HR P20171678 T1 HRP20171678 T1 HR P20171678T1 HR P20171678T T HRP20171678T T HR P20171678TT HR P20171678 T HRP20171678 T HR P20171678T HR P20171678 T1 HRP20171678 T1 HR P20171678T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- pharmaceutical preparation
- patient
- eating
- treatment
- Prior art date
Links
- 208000010235 Food Addiction Diseases 0.000 title claims 8
- 208000014679 binge eating disease Diseases 0.000 title claims 8
- 206010004716 Binge eating Diseases 0.000 title claims 6
- 208000032841 Bulimia Diseases 0.000 title claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 14
- 206010020710 Hyperphagia Diseases 0.000 claims 4
- 235000020830 overeating Nutrition 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 3
- 229960001058 bupropion Drugs 0.000 claims 3
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 3
- 229960003086 naltrexone Drugs 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 230000007423 decrease Effects 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 238000013265 extended release Methods 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (15)
1. Farmaceutski pripravak koji sadrži bupropion ili njegovu farmaceutski prihvatljivu sol, i naltrekson ili njegovu farmaceutski prihvatljivu sol naznačen time da je za uporabu za liječenje prejedanja ili kompulzivnog jedenja.
2. Farmaceutski pripravak za uporabu prema zahtjevu 1, naznačen time da dodatno sadrži: upućivanje pacijenta za dnevno davanje terapijski učinkovite količine.
3. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1-2, naznačen time da je indeks tjelesne mase pacijenta veći od ili jednak 25 kg/m2.
4. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1-3, naznačen time da pacijent ne pati od velikog depresivnog poremećaja.
5. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1-4, naznačen time da dodatno sadrži utvrđivanje da li pacijent pati od velikog depresivnog poremećaja.
6. Farmaceutski pripravak za uporabu prema zahtjevu 5, naznačen time da pacijent ne pati od bipolarnog poremećaja.
7. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1-6, naznačen time da je terapijski učinkovita količina naltreksona ili njegove farmaceutski prihvatljive soli 4 mg do 50 mg dnevno i terapijski učinkovita količina bupropiona ili njegove farmaceutski prihvatljive soli je 30 mg do 500 mg dnevno.
8. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1-7, naznačen time da pacijent je žena.
9. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1-8, naznačen time da se simptom ili mjera poremećaja prejedanja ili poremećaja kompulzivnog jedenja smanjuje za barem 5%.
10. Farmaceutski pripravak za uporabu prema zahtjevu 9, naznačen time da se smanjuje simptom ili mjera snage događaja prejedanja ili kompulzivnog jedenja.
11. Farmaceutski pripravak za uporabu prema zahtjevu 9, naznačen time da se smanjuje simptom ili mjera frekvencije događaja prejedanja ili kompulzivnog jedenja.
12. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1-11, naznačen time da se prejedanje ili kompulzivno jedenje kod pacijenta mjeri korištenjem skale prejedanja prije početka tretmana, te barem jednom nakon početka tretmana.
13. Farmaceutski pripravak za uporabu prema zahtjevu 12, naznačen time da se vrijednost skale prejedanja prije početka tretmana smanjuje za barem 10 nakon tretmana ili se smanjuje na manje od 17 nakon tretmana.
14. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1-13, naznačen time da pacijent je identificiran kao pacijent koji pati od ili ima rizik od poremećaja prejedanja ili poremećaja kompulzivnog jedenja pomoću primjene kontrolnog popisa skale prejedanja.
15. Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 1 do 14 naznačen time da dodatno sadrži:
identificiranje pacijenta koji pati od ili ima rizik od prejedanja ili kompulzivnog jedenja pomoću primjene kontrolnog popisa skale prejedanja, te pacijent ima indeks tjelesne mase (BMI) veći od ili jednak 27 kg/m2; i
davanje pacijentu 16 mg naltreksona s produženim otpuštanjem i 180 mg bupropiona s produženim otpuštanjem dva puta dnevno kroz period tretmana od više od 4 tjedna.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41935410P | 2010-12-03 | 2010-12-03 | |
| EP11844637.6A EP2646011B1 (en) | 2010-12-03 | 2011-12-02 | Methods for reducing binge or compulsive eating |
| PCT/US2011/063170 WO2012075453A1 (en) | 2010-12-03 | 2011-12-02 | Methods for reducing binge or compulsive eating |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171678T1 true HRP20171678T1 (hr) | 2017-12-15 |
Family
ID=46172302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171678TT HRP20171678T1 (hr) | 2010-12-03 | 2017-11-02 | Postupci za smanjenje prejedanja ili kompulzivnog jedenja |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20130252995A1 (hr) |
| EP (1) | EP2646011B1 (hr) |
| JP (1) | JP2014508717A (hr) |
| KR (1) | KR20140035319A (hr) |
| CN (1) | CN103298462A (hr) |
| AR (2) | AR084093A1 (hr) |
| AU (3) | AU2011336298B2 (hr) |
| BR (1) | BR112013015957B1 (hr) |
| CA (1) | CA2819003A1 (hr) |
| CL (1) | CL2013001565A1 (hr) |
| CY (1) | CY1119560T1 (hr) |
| DK (1) | DK2646011T3 (hr) |
| ES (1) | ES2647232T3 (hr) |
| HR (1) | HRP20171678T1 (hr) |
| HU (1) | HUE034641T2 (hr) |
| IL (1) | IL226483A0 (hr) |
| LT (1) | LT2646011T (hr) |
| MX (1) | MX350304B (hr) |
| NO (1) | NO2646011T3 (hr) |
| PL (1) | PL2646011T3 (hr) |
| PT (1) | PT2646011T (hr) |
| RS (1) | RS56548B1 (hr) |
| RU (1) | RU2620913C2 (hr) |
| SI (1) | SI2646011T1 (hr) |
| TW (2) | TWI536986B (hr) |
| WO (1) | WO2012075453A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2303085T3 (es) | 2003-04-29 | 2008-08-01 | Orexigen Therapeutics, Inc. | Composiciones que afectan a la perdida de peso. |
| BRPI0618918B8 (pt) | 2005-11-22 | 2021-05-25 | Nalpropion Pharmaceuticals Llc | uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| MX343867B (es) | 2006-11-09 | 2016-11-25 | Orexigen Therapeutics Inc | Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso. |
| MX2010012909A (es) | 2008-05-30 | 2011-02-25 | Orexigen Therapeutics Inc | Metodos para tratamiento de condiciones de grasa visceral. |
| AU2011203867B2 (en) | 2010-01-11 | 2015-12-03 | Nalpropion Pharmaceuticals Llc | Methods of providing weight loss therapy in patients with major depression |
| EP2858640B1 (en) | 2012-06-06 | 2020-03-25 | Nalpropion Pharmaceuticals LLC | Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2197250C2 (ru) * | 2000-10-30 | 2003-01-27 | Соколовский Сергей Ростиславович | Способ лечения наркоманий |
| ES2303085T3 (es) | 2003-04-29 | 2008-08-01 | Orexigen Therapeutics, Inc. | Composiciones que afectan a la perdida de peso. |
| US20070099947A1 (en) * | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| KR20190042766A (ko) | 2006-11-09 | 2019-04-24 | 오렉시젠 세러퓨틱스 인크. | 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형 |
| MX343867B (es) | 2006-11-09 | 2016-11-25 | Orexigen Therapeutics Inc | Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso. |
| GB2447949B (en) * | 2007-03-29 | 2010-03-31 | Renasci Consultancy Ltd | A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission |
| US8318813B2 (en) * | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
| US20100317572A1 (en) * | 2007-12-20 | 2010-12-16 | Neurosearch A/S | Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound |
| AU2011326173B2 (en) * | 2010-11-08 | 2015-08-27 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
-
2011
- 2011-12-02 LT LTEP11844637.6T patent/LT2646011T/lt unknown
- 2011-12-02 AR ARP110104511A patent/AR084093A1/es not_active Application Discontinuation
- 2011-12-02 SI SI201131336T patent/SI2646011T1/en unknown
- 2011-12-02 PT PT118446376T patent/PT2646011T/pt unknown
- 2011-12-02 JP JP2013542227A patent/JP2014508717A/ja active Pending
- 2011-12-02 EP EP11844637.6A patent/EP2646011B1/en active Active
- 2011-12-02 CN CN2011800595435A patent/CN103298462A/zh active Pending
- 2011-12-02 US US13/991,372 patent/US20130252995A1/en not_active Abandoned
- 2011-12-02 DK DK11844637.6T patent/DK2646011T3/da active
- 2011-12-02 ES ES11844637.6T patent/ES2647232T3/es active Active
- 2011-12-02 CA CA2819003A patent/CA2819003A1/en not_active Abandoned
- 2011-12-02 RU RU2013127420A patent/RU2620913C2/ru active
- 2011-12-02 HU HUE11844637A patent/HUE034641T2/en unknown
- 2011-12-02 NO NO11844637A patent/NO2646011T3/no unknown
- 2011-12-02 AU AU2011336298A patent/AU2011336298B2/en active Active
- 2011-12-02 KR KR1020137017316A patent/KR20140035319A/ko not_active Application Discontinuation
- 2011-12-02 RS RS20171107A patent/RS56548B1/sr unknown
- 2011-12-02 BR BR112013015957-0A patent/BR112013015957B1/pt active IP Right Grant
- 2011-12-02 TW TW100144461A patent/TWI536986B/zh active
- 2011-12-02 TW TW105105528A patent/TW201735912A/zh unknown
- 2011-12-02 WO PCT/US2011/063170 patent/WO2012075453A1/en active Application Filing
- 2011-12-02 MX MX2013006070A patent/MX350304B/es active IP Right Grant
- 2011-12-02 PL PL11844637T patent/PL2646011T3/pl unknown
-
2013
- 2013-05-21 IL IL226483A patent/IL226483A0/en unknown
- 2013-05-31 CL CL2013001565A patent/CL2013001565A1/es unknown
-
2017
- 2017-04-27 AU AU2017202793A patent/AU2017202793B2/en active Active
- 2017-11-02 HR HRP20171678TT patent/HRP20171678T1/hr unknown
- 2017-11-14 CY CY20171101188T patent/CY1119560T1/el unknown
-
2018
- 2018-06-04 AU AU2018203921A patent/AU2018203921A1/en not_active Abandoned
-
2021
- 2021-06-02 US US17/336,546 patent/US20210283126A1/en active Pending
- 2021-12-23 AR ARP210103652A patent/AR124497A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171678T1 (hr) | Postupci za smanjenje prejedanja ili kompulzivnog jedenja | |
| HRP20171256T1 (hr) | Farmaceutski pripravci karbetocina | |
| HRP20161444T1 (hr) | Farmaceutski pripravci koji sadrže lokalni anestetik kao što je bupivakain za lokalnu primjenu u usta ili grlo | |
| HRP20180942T1 (hr) | Liječenje negativnih simptoma shizofrenije s (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamidom i njegovim farmaceutski prihvatljivim solima | |
| HRP20171024T1 (hr) | Novi spoj, koristan u liječenju degenerativnih i upalnih bolesti | |
| IL217901B (en) | Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases | |
| HRP20161437T1 (hr) | Postupak hitne kontracepcije | |
| JP2010522242A5 (hr) | ||
| CL2011002248A1 (es) | Composicion farmaceutica oral de liberacion inmediata que comprende oxicodona y naloxona en una proporcion 2:1 en peso; uso de la composicion farmaceutica para tratar dolor intercurrente en paciente que sufren de dolor. | |
| HRP20130057T1 (hr) | Lijeäśenje progresivne neurodegenerativne bolesti ibudilastom | |
| JP2016147915A5 (hr) | ||
| IL198314A (en) | History of Quinuclidine of (hetero) Acrylic Cyclohepethecarboxylic Acid, Process of Preparation, Medicinal Preparations Containing Them and Use of Drug Preparation for Treatment | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| BRPI0806392A8 (pt) | uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica | |
| JP2018527305A5 (hr) | ||
| JP2012136529A5 (hr) | ||
| HRP20150120T1 (hr) | Materijal i metode za lijeäśenje poremeä†aja u razvoju ukljuäśujuä†i komorbidni i idiopatski autizam | |
| HRP20130123T1 (hr) | Postupak lijeäśenja bolesti | |
| JP2015514739A5 (hr) | ||
| HRP20230762T1 (hr) | Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama | |
| JP2011512394A5 (hr) | ||
| FR2937868B1 (fr) | Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| EA201491614A1 (ru) | Способ лечения гинекологических заболеваний | |
| EP2384745A3 (en) | Modified release pharmaceutical compositions of dexlansoprazole |